Pfizer Launches Generic Versions Of Ivomec Plus, Banamine
Pfizer Launches Generic Versions of Ivomec Plus, BanaminePfzier, Merial, Merck, Alverin Plus, Ivomec Plus, Banamine, Flunixamine, generic veterinary drugsMadison, N.J.-based Pfizer Animal Health unveiled on Tuesday, June 29, 2012, Alverin Plus (ivermectin/clorsulon) and Flunixamine (flunixin meglumine), generic versions of Merial’s Ivomec Plus and Merck Animal Health’s Banamine, respectively.Pfizer Animal Health unveiled on June 20, 2012, Alverin Plus (ivermectin/clorsulon) and Flunixamine (flunixin meglumine), generic versions of Merial’s Ivomec Plus and Merck Animal Health’s Banamine, respectively.newslinePfizer Launches Generic Versions of Ivomec Plus, BanaminePosted: June 20, 2012, 1:00 p.m. EDT
Madison, N.J.-based Pfizer Animal Health unveiled on Tuesday Alverin Plus (ivermectin/clorsulon) and Flunixamine (flunixin meglumine), generic versions of Merial’s Ivomec Plus and Merck Animal Health’s Banamine, respectively.
“Alverin Plus and Flunixamine allow Pfizer Animal Health the opportunity to deliver a wider portfolio of products, giving veterinarians, producers and owners expanded access to innovative products, solutions and services,” said Roger Saltman, DVM, MBA, group director of cattle and equine technical services for Pfizer Animal Health. “Whether we are expanding our product lines or providing world-class customer and technical support, our goal remains the same—to help keep animals healthy.”
Flunixamine is a nonsteroidal anti-inflammatory drug (NSAID) for use in horses and cattle and available in 100 mL and 250 mL glass bottles.
For horses, it is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders and visceral pain associated with colic, Pfizer reported.
For cattle, it is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis.
Alverin Plus will treat and control parasites in cattle, including adult liver flukes, gastrointestinal roundworms, lungworms, cattle grubs, sucking lice and mange mites. It will be available in 500 mL and 1,000 mL plastic bottles.
In an interview with Veterinary Practice News in August 2011, Clinton Lewis, Pfizer Animal Health’s president of U.S. operations, discussed, among other topics, Pfizer’s plans to begin offering generic drugs in the U.S. that “filled gaps” in its offering and how its acquisition of Alpharma facilitated that effort.
He also suggested that the unit was likely to be spun off, which Pfizer recently confirmed with the announcement of its plans to spin off the unit into a company called Zoetis by July 2013.
The purpose of the University of California, Davis School of Veterinary Medicine study is to use stem cells to treat cats with chronic gingivostomatitis that have not had full mouth dental extractions.